Vemurafenib and cutaneous adverse events - report of five cases

• Glavni autori: Giselle de Barros Silva (Autor), Adriana Pessoa Mendes (Autor), Mariana Petaccia de Macedo (Autor), Clóvis Antônio Lopes Pinto (Autor), Ivana Lameiras Gibbons (Autor), João Pedreira Duprat Neto (Autor)
• Format: Knjiga
• Izdano: Sociedade Brasileira de Dermatologia, 2015-06-01T00:00:00Z.
• Teme: article
• Online pristup: Connect to this object online.

AbstractVemurafenib is a selective inhibitor of V600E-mutant BRAF protein used to treat metastatic and unresectable melanoma. Clinical trials have shown increased overall survival and progression-free survival in patients treated with Vemurafenib. However, cutaneous adverse events are common during...